Abstract

Disclosed in the present invention is a crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.

IPC Classes  ?

• C07D 215/22 - Oxygen atoms attached in position 2 or 4
• A61K 9/20 - Pills, lozenges or tablets

Abstract

A crystalline form of fluvatinib or fluvatinib methanesulfonate, and a preparation method therefor. The crystalline form I of the fluvatinib has characteristic diffraction peaks as shown in FIG. 1. The crystalline form of the fluvatinib methanesulfonate may take multiple forms, including seven crystalline forms, forms I-VII, wherein crystalline form III has characteristic diffraction peaks as shown in FIG. 9. Said crystalline forms are suited to manufacturing processes for fluvatinib methanesulfonate formulations.

IPC Classes  ?

• C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/47 - QuinolinesIsoquinolines
• C07C 303/32 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
• C07C 303/44 - SeparationPurification
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the field of pharmaceutical chemistry, and particularly to a crystal form of Abiraterone propionate and a preparation method therefor. Characteristic diffraction peaks occur at positions, where the 2θ value is 5.7°, 11.9°, 12.4°, 14.9°, 15.8°, 16.7°, 18.5°, 19.1°, 21.7°, 22.4°, and 39.9°±0.2°, in an X-ray powder diffraction spectrum of the crystal form of Abiraterone propionate.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton

Abstract

Disclosed are a veliparib crystal form A and a preparation method thereof. 2θ values of an X-ray powder diffraction pattern of the veliparib crystal form A have characteristic diffraction peaks at 9.39 ± 0.2°, 13.38 ± 0.2°, 17.25 ± 0.2°, 17.70 ± 0.2°, 18.94 ± 0.2°, 21.79 ± 0.2°, 22.77 ± 0.2°, 24.65 ± 0.2°, 28.98 ± 0.2°, 31.60 ± 0.2°, and 36.61 ± 0.2°. The preparation method of the veliparib crystal form A is easy to perform, provides a high yield, high purity, and stability, and is suitable for manufacturing a preparation of the veliparib crystal form A.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention relates to the field of pharmaceutical chemistry, and particularly to a crystal form of Abiraterone propionate and a preparation method therefor. Characteristic diffraction peaks occur at positions, where the 2θ value is 5.7°, 11.9°, 12.4°, 14.9°, 15.8°, 16.7°, 18.5°, 19.1°, 21.7°, 22.4°, and 39.9°±0.2°, in an X-ray powder diffraction spectrum of the crystal form of Abiraterone propionate.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 35/00 - Antineoplastic agents
• A61P 13/08 - Drugs for disorders of the urinary system of the prostate

Abstract

The present invention belongs to the technical field of pharmaceutical chemistry. Disclosed are quinoline derivates, preparation method therefor, and application thereof. Compounds provided by the present invention are the compounds represented by formula I or optical isomers, racemates, diastereoisomers, pharmaceutically acceptable salts or solvates thereof. The compounds have a significant killing effect on Mycobacterium tuberculosis, and can be used to prepare medicines for treating or preventing diseases or symptoms caused by the infection of Mycobacterium tuberculosis.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61P 31/06 - Antibacterial agents for tuberculosis
• C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
• C07D 213/50 - Ketonic radicals
• C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Abstract

A stable oral solid drug composition of abiraterone comprises abiraterone acetate and citrate which serves as a pharmaceutical adjuvant, wherein the weight ratio of citrate to abiraterone acetate is 1:100 to 1:5.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders.

IPC Classes  ?

• A01N 33/02 - AminesQuaternary ammonium compounds
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61K 9/70 - Web, sheet or filament bases
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/06 - OintmentsBases therefor
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof

Abstract

A transdermal patch of Rasagiline comprises Rasagiline or pharmaceutically acceptable salts thereof, a base substance and an inert back layer. The oxygen transmissivity of the back layer is not more than 100 cm3 /m2 /24h，which can effectively reduce the volatilization of the Rasagiline from the back layer which results in decreased content, thus a long term sustained treatment effect is ensured.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Disclosed is a preparation method for a morphinan bromide quaternary ammonium salt as represented by Formula (I). The method comprises: transforming a compound as represented by Formula (II) in a compound as represented by Formula (I) by an ion-exchange using a brominated strongly basic anion-exchange resin. The definitions of A, R1, R1 and X- found in Formula (I) and Formula (II) are as presented in the description.

IPC Classes  ?

• C07D 489/08 - Oxygen atom

Abstract

Three new crystalline forms of pemetrexed diacid, preparation methods and uses thereof are disclosed. These preparation processes are simple and have better practicality.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

A preparation method of ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate as a key intermediate of febuxostat is provided. The preparation method comprises: using thioacetamide and p-cyanophenol as raw materials which are reacted in an acid aqueous solution to obtain 4-hydroxy thiobenzamide, and reacting 4-hydroxy thiobenzamide with ethyl 2- chloroacetoacetate to obtain ethyl 2-(4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate, and reacting the obtained compound with methenamine in the presence of polyphosphoric acid and methanesulfonic acid to obtain ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate.

IPC Classes  ?

• C07C 237/48 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 9/107 - Emulsions
• A61K 9/70 - Web, sheet or filament bases
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/24 - Antidepressants

Abstract

The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and antioxidant used as stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film agent, spraying agent and solution etc. The composition can be used to prevent or treat mental disorders.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 9/70 - Web, sheet or filament bases
• A61K 9/107 - Emulsions
• A61K 9/06 - OintmentsBases therefor
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/24 - Antidepressants

Abstract

Three new crystalline forms of Agomelatine, their preparation methods and the pharmaceutical compositions containing them and their preparation use of drug used for curing the diseases of central nervous system are provided. These three new crystalline forms of Agomelatine have the advantage of high stability and easy preparation and are suitable for the production of pharmaceutical preparation.

IPC Classes  ?

• C07C 233/18 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61P 5/00 - Drugs for disorders of the endocrine system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

+.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

High purified (2β,3α,5α,16β,17β) -2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol (formula III) or composition containing it and their use in preparing rocuronium bromide (formula I) are disclosed.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps

Abstract

A febuxostat which purity is no less than 99.0％, method for preparation thereof, and pharmaceutical composition thereof. The said method for preparation includes recrystalling febuxostat in mixed solvent. The said pharmaceutical composition can be used in manufacture of medicaments for treating diseases associated with hyperuricemia.

IPC Classes  ?

• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/426 - 1,3-Thiazoles
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

Three new crystalline forms of pemetrexed diacid, preparation methods and uses thereof. These preparation processes are simple and have better practicality.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems

Abstract

The invention discloses morphinan derivatives and their preparation method, especially discloses ketal hydroxyl protected compounds of morphinan derivatives and their preparation method, and the method for preparing corresponding alkylated morphinan derivatives using the said ketal hydroxyl protected compounds as intermediates, and more especially discloses ketal hydroxyl protected compound intermediates of methylnaltrexone for preparing methylnaltrexone and the method for preparing methylnaltrexone through said intermediates.

IPC Classes  ?

• C07D 489/08 - Oxygen atom
• C07D 489/09 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems

Abstract

A transdermal patch of rasagiline or pharmaceutically acceptable salts thereof for treating or preventing nervous system diseases. Particularly, a stable and release-controlled transdermal patch of rasagiline is provided, wherein the patch contains rasagiline or pharmaceutically acceptable salts thereof and at least one hydrophilic polymer matrix, moreover,  the pH value of the patch is less than 7.0. The patch has predominant stability and can well control the transdermal release characteristics of rasageline.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 9/70 - Web, sheet or filament bases
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A purification method of pemetrexed salts by means of salting-out. The pemetrexed salts are defined as formula (III) in which, (1) If M3+ is H+, then M1+ and M2+ are H+, Li+, Na+ or K+ independently. M1+ and M2+ are the same or not ,but they can not be H+ simultaneously; (2)If M3+ is Li+, Na+ or K+, then M1+ and M2+ are Li+, Na+ or K+ independently. M1+, M2+ and M3+ are the same or not.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

The medicine composition containing abafungin is provided in the present invention, and the said composition contains abafungin and other antibacterial agents. The use of the said medicine composition for treating fungus infections or fungus and bacteria mixed infections is also provided in the present invention.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/65 - Tetracyclines
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/04 - Nitro compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/107 - Emulsions
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics

Abstract

The invention provides preparation method of thioureas or salts thereof. In particular, the invention provides method of preparing thioureas by reacting cyanamides or salts thereof with thioamides in proper acidic medium. The product can be used to prepare 2-aminothiazoles, such as antimycotic abafungin.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 239/16 - Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
• C07C 335/02 - Thiourea
• C01C 3/16 - CyanamideSalts thereof

Abstract

The present application belongs to pharmaceutical technology field. Three new crystal types of 2-(3-cyano-4-isobutyloxy) phenyl-4-methyl-5-thiazolecarboxylic acid (febuxostat) i.e. crystal types H, I and J and their preparation methods. Pharmaceutical compositions containing the new crystal types and the uses of crystal types as pharmaceutical medicaments for treatment diseases relating to excessive uric acid. Furthermore, the present application discloses X-ray diffraction characteristic absorption peak and IR absorption peak.

IPC Classes  ?

• C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/426 - 1,3-Thiazoles
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

An antimycotic pharmaceutical composition comprising the 2-aminothiazoles of the general formula (I) and corticoid drugs and the use of which for the treatment or prevention skin infection caused by fungus, wherein the definition of substituent group of general formula (I) as described in the description. Particularly, the antimycotic pharmaceutical composition can be used to treat or prevent skin infection caused by fungus, superficial fungal diseases, itching, the mixed infection caused by fungus and bacterium or various dermatitis

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/345 - Nitrofurans
• A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
• A61P 17/00 - Drugs for dermatological disorders
• A61P 31/10 - Antimycotics
• A61P 31/02 - Local antiseptics

Abstract

A transdermal patch of rasagiline for treatment or prophylaxis of nervous system disease and its preparation process, comprises: a backing layer inert to the components of the matrix a matrix layer contg. rasagiline and its or its salt, and a removable protective layer, characterised in that the matrix is an adhesive system having distribured therein as polymer and organic or inorganic bulking agent and dermal penetration enhancer, the reservoir in the matrix layer contains rasagiline, said polymer is based on organic macromolecular material and useful as the active substance reservoir and adhesive.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention discloses a new pharmaceutical composition comprising, in well-distributed powder form : iron-saccharide complex and salt agent in a suitable amount or other excipient . It also discloses the process for preparation the composition , wherein the salt or other excipient is added before iron-saccharide complex is being dried . This improved process make API manufacturer prepare the hematinic powder which can be used just mixed with water , moreover , the powder is easy to reconstitute in water by the ordinary manufacturer .

IPC Classes  ?

• A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/295 - Iron group metal compounds
• A61P 7/06 - Antianaemics

Abstract

A pharmaceutical composition for treating gout and its application in preparation of medicines for treating gout are provided. The said pharmaceutical composition comprises effective amount of febuxostat or its pharmaceutical salts or its solvates and a uric acid eliminant.

IPC Classes  ?

• A61K 31/425 - Thiazoles
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/08 - Solutions
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

The invention discloses a process for preparing multinuclear ferric hydroxide-saccharidic complexes, comprising: titrating an aqueous solution of iron salt with an aqueous solution of alkali to a final pH of 68 under 520 , collecting the multinuclear ferric hydroxide from the reaction product by conventional method; maintaining a reaction mixture of multinuclear ferric hydroxide, saccharides and solution of alkali for 1040 hours under a temperature of 106125 and pH being 1012, and obtaining the crude product having an isoelectric point of 4.45.3 and a weight average molecular weight of 20000100000 Daltons, and then collecting the multinuclear ferric hydroxide-saccharidic complexes from the crude product. The process can control the molecular weight of the multinuclear ferric hydroxide-saccharidic complexes exactly while not influencing other characteristics of the product such as content of saccharides or isoelectric point etc, and which is simple and readily applicable in industry.

IPC Classes  ?

• C08B 37/02 - DextranDerivatives thereof
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• C07F 15/02 - Iron compounds